Jiangsu Weiqida Pharmaceutical Co., Ltd. (formerly known as Shanghai Shyndec Pharmaceutical Haimen Co., Ltd.) is the third subsidiary of Shanghai Shyndec Pharmaceutical Co., Ltd. (stock code: 600420), a chemical and pharmaceutical industry platform under China National Pharmaceutical Group Co., Ltd. (Sinopharm). It is the wholly-owned subsidiary of Sinopharm Weiqida Pharmaceutical Co., Ltd. Jiangsu Weiqida was established in Nantong City, Jiangsu Province in February 2010 with a registered capital of 800 million yuan. The company is positioned as an exclusive high-end and characteristic API R&D and production base. Its main products cover antiviral, anti-infective, cardiovascular and cerebrovascular, and general health fields, and are exported to the international market, covering more than 20 countries and regions. It has a high market share. The company is committed to become a professional, service, innovative and reliable pharmaceutical service platform. “All for health, Health for all”. Through years of precipitation, we have complete production technology capabilities, perfect quality management, and EHS management systems, providing core services from pilot scale-up to commercial production and various certification, registration support to global customers. We have successively passed NMPA, FDA, WHO and other authoritative certifications, and have provided long-term services for world-renowned pharmaceutical companies.
Jiangsu Weiqida has a R&D/technology center, relying on the China State Institute of Pharmaceutical Industry under the China National Pharmaceutical Group, with strong R&D technology, professional talent team and advanced equipment. It has passed the national intellectual property management certification, and is certificated as “Jiangsu High-tech Enterprise”. It has been successively recognized as “Jiangsu High-end API Synthesis Engineering Technology Research Center”, “Jiangsu Enterprise Technology Center”, and “Jiangsu Pharmaceutical Industry Integrity Enterprise”. Azithromycin, L-α-Glycerophosphoryl Choline, and Nebivolol Hydrochloride were certified as high-tech products. In the future, the company will actively promote R&D innovation, focusing on the development of high-tech, high value-added, low-emission featured products, and building the company into a CDMO customized processing industry base.